Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1101 - 1125 of 2615 in total
BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis).
Investigational
Experimental
Matched Synonyms: … 9-Oxo-N-(2H-tetrazol-5-yl)-9H-xanthene-2-sulfonamide …
Matched Name: … N-(1,4-dihydro-5H-tetrazol-5-ylidene)-9-oxo-9H-xanthene-2-sulfonamide …
Matched Iupac: … N-(4,5-dihydro-1H-1,2,3,4-tetrazol-5-ylidene)-9-oxo-9H-xanthene-2-sulfonamide …
Experimental
Matched Name: … [(3S)-9-hydroxy-1-methyl-10-oxo-4,10-dihydro-3H-benzo[g]isochromen-3-yl]acetic acid …
Matched Iupac: … 2-[(3S)-9-hydroxy-1-methyl-10-oxo-3H,4H,10H-naphtho[2,3-c]pyran-3-yl]acetic acid …
Investigational
Investigational
Experimental
Matched Name: … 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- …
Matched Iupac: … 8-[(2H-1,3-benzodioxol-5-yl)methyl]-9-butyl-9H-purin-6-amine …
WVE-003 is an allele-selective antisense oligonucleotide that works to selectively reduce the toxic mutant huntingtin (mHTT) protein.
Investigational
Investigational
VS-5584 has been used in trials studying the treatment of Lymphoma, Metastatic Cancer, and Non Hematologic Cancers.
Investigational
Matched Synonyms: … 2-pyrimidinamine, 5-(8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl)- ... 5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6yl]-2-pyrimidinamine …
Matched Iupac: … 5-[8-methyl-2-(morpholin-4-yl)-9-(propan-2-yl)-9H-purin-6-yl]pyrimidin-2-amine …
Experimental
Investigational
IK-930 is an oral, paralog-selective TEAD inhibitor.
Investigational
Experimental
Matched Synonyms: … 9-phenanthrenamine ... 9-phenanthrylamine ... phenanthren-9-amine …
Matched Name: … 9-Aminophenanthrene …
Matched Iupac: … phenanthren-9-amine …
Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
Investigational
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
R-95845 is an inhibitor of HIV-1 reverse transcriptase.
Experimental
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
Investigational
SR-9009 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
SR-9011 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
GS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).
Investigational
Matched Iupac: … 2-methylpropyl (2S)-2-{[({2-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]ethoxy}methyl)({[(2S)-1-(2-methylpropoxy …
ILS-920 is under investigation in clinical trial NCT00827190 (Study Evaluating Single Ascending Doses Of ILS-920).
Investigational
Matched Iupac: … dimethoxy-3,9,24,26,30,32-hexamethyl-34-phenyl-20,35,38-trioxa-13,34-diazatetracyclo[31.2.2.1^{6,10}.0^ …
REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).
Investigational
Investigational
Displaying drugs 1101 - 1125 of 2615 in total